@DietrichLab

Haematology research group @UniklinikDUS & @uniklinik_hd working on disease biology, resistance markers and personalized medicine.

 Düsseldorf and Heidelberg
dietrichlab.de
Joined April 2021
  • Tweets72
  • Following50
  • Followers242
20Media
November 14th: Free Webinar on #functionalprecisionmedicine using ex vivo drug screening in clinical application. @MedChemExpress
2
414
Delighted to share our newest publication on CAR+ T-cell lymphoma after #CART therapy. @HHU_de @UniklinikDUS
NEJM
@NEJM2 Oct 2024
Shortly after a patient received CAR T-cell therapy for relapsed CNS lymphoma, an aggressive CAR+ T-cell lymphoma was diagnosed. Subsequent analysis revealed the presence of an abnormal clone in an early apheresis specimen. Read the Brief Report: nej.md/3BuToVM
A figure showing the distribution of mutations detected by DNA deep sequencing of flow-sorted hematopoietic-cell fractions at three time points: T1 (leukapheresis material collected for autologous stem-cell transplantation 217 days before CAR T-cells infusion), T2 (leukapheresis material collected for CAR T-cell preparation 140 days before infusion), and T4 (CAR+ T-cell lymphoma sample obtained 60 days after CAR T-cells infusion), according to color-coded categories of variant allele frequency (VAF).

ALT A figure showing the distribution of mutations detected by DNA deep sequencing of flow-sorted hematopoietic-cell fractions at three time points: T1 (leukapheresis material collected for autologous stem-cell transplantation 217 days before CAR T-cells infusion), T2 (leukapheresis material collected for CAR T-cell preparation 140 days before infusion), and T4 (CAR+ T-cell lymphoma sample obtained 60 days after CAR T-cells infusion), according to color-coded categories of variant allele frequency (VAF).

4
10
1,478
Congratulations to Peter from our team on his funding from the @EKFStiftung. In his project he will investigate mechanisms of #immune control in #lymphoma @HHU_de @UniklinikDUS using @AkoyaBio PhenoImager Fusion based cellular characterisation and other #spatial omics techniques
Else Kröner-Fresenius-Stiftung
@EKFStiftung29 Aug 2024
Die @EKFStiftung vergibt an sechs besonders begabte junge Ärztinnen und Ärzte die Else Kröner Memorialstipendien in Höhe von je 250.000 Euro. Herzlichen Glückwunsch! 🥳 @GrasslNiklas , @DrHeinrichB, @DietrichLab u. a. ➡️ ekfs.de/aktuelles/presse/fre…
6
10
2,085
🔬 Zusammensetzung von Immunzellen im Gewebe bei #Lymphdrüsenkrebs charakterisiert: Normalerweise erkennen Immunzellen körperfremde Angreifer wie Bakterien oder erkrankte Zellen und vernichten diese. Bei Krebserkrankungen sind diese Mechanismen gestört. 1/ Foto: @UniklinikDUS
Foto von Dr. Peter Bruch und Prof. Dr. Sascha Dietrich

ALT Foto von Dr. Peter Bruch und Prof. Dr. Sascha Dietrich

1
1
3
1,583
💫NEW: Roider, Baertsch (@marc_a_baertsch) et al. present a spatially resolved resource map of the T cell infiltration landscape across and within patients with distinct B cell #nonHodgkin #lymphoma entities. @GarryPNolan @wolfgangkhuber @DietrichLab nature.com/articles/s41556-0…
2
9
24
5,283
#Tcell infiltration differs strongly between and within #lymphoma entities. These differences arise partly from clonal expansion and are linked to patient survival. Find our most recent #openaccess publication @NatureCellBio doi.org/10.1038/s41556-024-0…
Single cell RNA sequencing alongside full-length T cell receptor repertoire data were mapped to the CITE-seq reference data. Lines connect all regulatory T effector memory 2 cells with other cells with the same T cell receptor clonotype.

ALT Single cell RNA sequencing alongside full-length T cell receptor repertoire data were mapped to the CITE-seq reference data. Lines connect all regulatory T effector memory 2 cells with other cells with the same T cell receptor clonotype.

2
8
31
3,080
more replies
This project - like most of our research - would have been impossible without great #collaboration partners! Thank you @wolfgangkhuber @marc_a_baertsch @GarryPNolan @embl @HHU_de @uniklinik_hd @DKFZ @LabTidow @MMPU_Heidelberg and many more
1
2
7
650
Further, a great thank you to the patients that have agreed to the #biobanking that made this research possible and all the funders @BMBF_Bund @EKFStiftung @dfg_public
6
328
This week we had great scientific retreat at Schloss Mickeln @HHU_de. It was great to hear all our young motivated students present their ambitious research projects alongside lively discussions and social events.
1
10
1,126
Our work on ex vivo drug response profiling has been highlighted as paper of the month @EKFStiftung. Thank you very much for the continued support of our research! ekfs.de/en/current-topics/pa…
Cancer cells can be isolated from peripheral blood sampling, bone marrow or lymph node. These cells can then be treated outside the body with a wide selection of drugs to predict the most effective therapy. Illustration by @DrawImpact

ALT Cancer cells can be isolated from peripheral blood sampling, bone marrow or lymph node. These cells can then be treated outside the body with a wide selection of drugs to predict the most effective therapy. Illustration by @DrawImpact

2
3
1
16
1,705
Join our medical informatics team at the @HHU_de and @UniklinikDUS: Clinical data collection and processing workflows that improve diagnostics and risk assessement by applying new methods from fields such as #MachineLearning, statistics and #DataScience jobvector.de/jobs/universit%…
5
6
1,029
Looking for an exhaustive review on follicular #lymphoma tumor microenvironment? Please have a look to our work just published in @BloodJournal 👇 Thanks to @DietrichLab and Camille Laurent @CarnotCALYM for their insightful contribution! sciencedirect.com/science/ar…
5
12
1,133
Congratulations to Peter-Martin Bruch from our lab, who won this years Dr.-Günther- und Imme-Wille award @HHU_de for his work on resistance mechanisms in #lymphoma.
#GFFU president Eduard H. Dörrenberg, Peter-Martin Bruch and Prof. Dr. Stefanie Ritz-Timme, head of the Dr. Günther and Imme Wille-foundation curatorium (left to right)

ALT #GFFU president Eduard H. Dörrenberg, Peter-Martin Bruch and Prof. Dr. Stefanie Ritz-Timme, head of the Dr. Günther and Imme Wille-foundation curatorium (left to right)

2
11
2,164
Excited to present our results on #bpdcn at the @Stemline BPDCN summit.
3
357
Sascha Dietrich @dgho_eV #dgho2023 on aggressive #lymphoma. We are looking forward to contribute towards improved diagnosis, stratification and treatment with our #translationalresearch.
12
796
Congratulations to Peter from our lab @UniklinikDUS @HHU_de for winning the @dgho_eV dissertation #award for his work on microenvironment - drug interactions in #CLL
1
2
14
1,487
Really happy this long-term project is finally published. #FunctionalPrecisionMedicine has the potential to tackle overtreatment, improve therapy stratification and reduce unnecessary side effects.
Nature Cancer@NatureCancer10 Oct 2023
💫ONLINE NOW @NatureCancer “ Ex vivo drug response profiling for response and outcome prediction in hematologic malignancies: the prospective non-interventional SMARTrial” by @DietrichLab & Co. #leukemia #lymphoma👇 nature.com/articles/s43018-0… rdcu.be/dob0I
9
728
Can we predict #cancer therapy response by ex vivo drug response profiling? Published today as #OpenAccess in @NatureCancer the prospective non-interventional SMARTrial seeks to answer this question for #leukemia and #lymphoma. nature.com/articles/s43018-0…
Primary tumor cells are isolated from tissue biopsies, bone marrow or peripheral blood. By treating these cells with clinically available drugs ex vivo, individual vulnerabilities are identified which can be used to treat the patient with the most effective treatment. Many thanks to Emma from @DrawImpacts for this beautiful illustration of the study principle.

ALT Primary tumor cells are isolated from tissue biopsies, bone marrow or peripheral blood. By treating these cells with clinically available drugs ex vivo, individual vulnerabilities are identified which can be used to treat the patient with the most effective treatment. Many thanks to Emma from @DrawImpacts for this beautiful illustration of the study principle.

3
11
35
4,930
In short: Ex vivo drug response is associated with therapy response to chemotherapeutic drugs, in particular in #AML beyond genetic risk groups. While additional #ClinicalTrials are needed, this is a big step towards using functional profiling for #PrecisionMedicine.
Left: Overview of AML sample cohort. The inner circle represents ELN-22 risk groups in total numbers, and the outer circle represents the distribution of in vivo responders and non-responders in ELN-22 risk groups. Right: Viability after ex vivo treatment with daunorubicin and cytarabine separated by ELN-22 risk groups. For details see https://www.nature.com/articles/s43018-023-00645-5/figures/4.

ALT Left: Overview of AML sample cohort. The inner circle represents ELN-22 risk groups in total numbers, and the outer circle represents the distribution of in vivo responders and non-responders in ELN-22 risk groups. Right: Viability after ex vivo treatment with daunorubicin and cytarabine separated by ELN-22 risk groups. For details see https://www.nature.com/articles/s43018-023-00645-5/figures/4.

1
5
8
781
Many thanks to all those who made this project possible. First and foremost the patients who participated in the trial. Further, all those collaborators without whom this project would have been impossible and the funders who have so generously supported this research.
201
Load more